Similar to the US, Canada has a patent linkage system that requires generics to address certain patents before obtaining regulatory approval of drugs. Although in theory the two systems are similar, in practice there are nuances that make them different. Published in LMG Life Sciences, 2, pp. 153-154.
Article
The Same But Different: Patent Linkage in Canada
2013
Republication Requests
To obtain permission to republish this publication or any other publication, contact Erica Wirthlin at wirthline@bennettjones.com.
For Informational Purposes Only
This publication provides an overview of trends and legal updates for informational purposes only. For personalized legal advice, please contact the authors.
From the Same Authors
See AllBlog
Life Sciences Collaborations and the Risk of Joint Patent Infringement
May 26, 2026Emily P. Kettel & Vincent M. de Grandpré
Blog
Competition Tribunal Issues First-of-Its-Kind Decision in Private Abuse of Dominance Case Against Major Pharma Manufacturer
January 24, 2025Emrys Davis, Emily P. Kettel & Christina Skinner
Latest Insights
See All Insights See AllBlog
OPC Issues New PIPEDA Guidance on Assessing Third-Party Service Providers
September 14, 2026 & 2 more
Blog
Government of Canada Reduces the Scope of the Project List under the Impact Assessment Act
September 11, 2026Ashley M. White, Martin Ignasiak KC & Nathan Murray
Blog
BC Signs DRIPA Agreement Requiring Simpcw Consent for Yellowhead Copper Project
September 10, 2026 & 1 more




















